The unlabeled AEs not previously documented in FDA-approved information included photosensitivity reaction, dysmenorrhea, oligomenorrhea, increased gamma-glutamyltransferase, decreased blood iron, increased blood calcium, prolonged prothrombin time, increased red cell distribution width, hepatitis A, seasonal allergy, vanishing bile duct syndrome, cholecystitis, hunger, soft feces, eye color change, and blepharospasm. This evidence concerns the gene F2 and Cholecystitis.